Lab guide · Growth-hormone axis
What Is CJC-1295 No DAC? Modified GHRH(1-29) Peptide Research Overview
What is CJC-1295 No DAC? It is the market name for modified GRF(1-29), a 29-residue growth hormone-releasing hormone analogue with four stabilising substitutions and no albumin-binding group. This guide explains its structure, how it differs from the DAC version and from native GHRH(1-29), and what is known about its pharmacology.
Key takeaways
- CJC-1295 No DAC is the market name for modified GRF(1-29): a 29-residue amide with D-Ala2, Gln8, Ala15 and Leu27 substitutions, formula C152H252N44O42 and mass about 3367.9 g/mol.
- Strictly, CJC-1295 refers to the version with a drug affinity complex (DAC); the no-DAC form is a different molecule with a much shorter duration of action.
- It acts at the GHRH receptor, and the substitutions are designed to resist DPP-4 cleavage and remove oxidation- and deamidation-prone residues.
- Published human pharmacokinetic and efficacy data concern the DAC form, not the no-DAC peptide, so they should not be transferred between the two.
What is CJC-1295 No DAC?
So, what is CJC-1295 No DAC? The name is a market label. In the literature, the compound is modified GRF(1-29) (mod GRF), a tetrasubstituted analogue of the first 29 residues of human growth hormone-releasing hormone (GHRH). The compound named CJC-1295 in the Jetté et al. (2005, Endocrinology) paper is the longer-acting form that carries a maleimide-based drug affinity complex (DAC) on an added C-terminal lysine. Without that group, the peptide is a distinct molecule with different pharmacokinetics. Baltic Peptides covers the other form in What is CJC-1295 With DAC.
Research use only. This overview summarises published laboratory and animal research. Baltic Peptides supplies this compound for in-vitro and preclinical research by qualified researchers; it is not a medicine and is not for human or veterinary use.
Chemical structure and specifications
| Property | Value |
|---|---|
| Sequence | Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2 |
| Length | 29 residues, C-terminal amide |
| Molecular formula | C152H252N44O42 |
| Molecular weight | ≈3367.9 g/mol (average); 3365.894 Da monoisotopic, calculated |
| PubChem CID | 91976842 |
| Substitutions vs native GRF(1-29) | Ala2→D-Ala, Asn8→Gln, Gly15→Ala, Met27→Leu |
The formula and mass match the PubChem record, and the sequence composition reproduces that formula. Registry numbers for the CJC-1295 family are inconsistent between suppliers, so this article does not quote a CAS number; identity should be confirmed from the batch COA and mass.
Discovery and research history
The CJC-1295 programme came from a drug-affinity-complex approach to extending peptide half-life. Jetté et al. (2005, Endocrinology) screened albumin-conjugated GRF analogues in rats, and CJC-1295, a tetrasubstituted form of hGRF(1-29) with a maleimide-derivatised lysine at the C terminus, produced a four-fold greater GH area under the curve over two hours than hGRF(1-29) and persisted in plasma beyond 72 hours.
The no-DAC peptide is the stabilised GRF(1-29) scaffold from that work, sold separately. Human studies of CJC-1295 used the DAC form (Teichman et al. (2006)).
Mechanism: GHRH receptor agonism
Receptor and signalling
Like native GHRH, the peptide binds the GHRH receptor on anterior pituitary somatotrophs, a Gs-coupled receptor whose activation raises cAMP and drives GH gene transcription and release.
What the four substitutions do
Native GRF(1-29) is a rapidly cleaved substrate, and the D-Ala at position 2 is designed to block cleavage by dipeptidyl peptidase-4 (DPP-4) at the N-terminus. Gln replaces an asparagine that can deamidate, Ala at position 15 is intended to stabilise the helix, and Leu replaces the oxidation-prone methionine at position 27. These are design rationales; they extend exposure from minutes to a few tens of minutes, not to days.
Main research areas
- GHRH receptor pharmacology: binding and cAMP assays in pituitary cell models.
- Pulsatile GH secretion: rodent studies of pulse amplitude and frequency.
- IGF-1 axis: hepatic IGF-1 as a downstream readout.
- Combination designs: pairing a GHRH analogue with a ghrelin-receptor agonist such as ipamorelin.
What published studies actually show
| Evidence type | What is reported |
|---|---|
| Chemical facts | Formula and mass are database-verifiable; the substitutions are described in the literature. |
| Rat studies | The DAC form raised GH and persisted in plasma; the no-DAC scaffold is the shorter-acting comparator. |
| Human studies | Published human pharmacokinetic and pharmacodynamic data concern the DAC form (Teichman et al. (2006)). No published human study of the no-DAC peptide was found in the sources reviewed. |
| Unconfirmed | Half-life of the no-DAC form in humans, and any effect outside experimental settings. |
Supplier documents quote a half-life of about 30 minutes for the no-DAC peptide. That figure is a design expectation, not a peer-reviewed human measurement.
Scientific limitations and open questions
- The name “CJC-1295” is used for two molecules with different pharmacokinetics.
- Human data are for the DAC form; the no-DAC peptide lacks published human pharmacokinetics in the sources reviewed.
- Design rationales for each substitution are inferred from structure and are not all individually tested.
- GHRH analogues are prohibited in sport under the WADA Prohibited List.
- Registry numbers and masses vary between suppliers, so identity must be confirmed analytically.
Analytical and laboratory considerations
Intact-mass analysis should show about 3367.9 Da, which also rules out the DAC form (a maleimide-bearing peptide of about 3647 Da on supplier data). HPLC should resolve truncated sequences, deamidation products and D-Ala racemisation, since an L-Ala impurity has the same mass but is cleaved by DPP-4. With methionine replaced by leucine there is no obvious oxidation-prone residue.
See how to store peptides and the guide to reading a peptide COA. Batch reports are on the COA page, and formats are on the CJC-1295 No DAC product page.
Sources and further reading
- Jetté L. et al. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. PubMed
- Teichman S.L. et al. (2006). Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 91(3):799-805. PubMed
- PubChem compound record for CJC1295 without DAC (CID 91976842). PubChem
All Baltic Peptides products are supplied strictly for laboratory research use. They are not medicines, supplements or food and are not for human or animal use. This article summarises published research for educational purposes only and does not describe any use in people.
FAQ
Common questions
What is CJC-1295 No DAC?
Is CJC-1295 No DAC the same as Mod GRF 1-29?
What is the molecular weight and formula of CJC-1295 No DAC?
What does DAC stand for?
Why does CJC-1295 No DAC have four amino acid substitutions?
Is there human data on CJC-1295 No DAC?
How is CJC-1295 No DAC different from Sermorelin?
Keep reading
Related reading
CJC-1295 No DAC
Current batches, formats and the COA for CJC-1295 No DAC.
What is CJC-1295 With DAC?
How albumin binding changes the pharmacokinetics of the same scaffold.
Peptide blends explained
Why component research does not define a combined formulation.
Research-grade CJC-1295 No DAC, tested before it ships
Independent HPLC and mass spec results for every batch, dispatched from the EU.
